

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Strategic Trading Analysis

Based on the comprehensive "Stock Detailed Analysis Report" for **SUNPHARMA.NS** (Sun Pharmaceutical Industries Ltd.), here is my assessment as a Positional Equity Trader.

Step 1: Audit the Data

- **Data Present:**
 - **Price Action:** Daily and Weekly charts (candlesticks), Multi-timeframe analysis.
 - **Trend Indicators:** Moving Averages (EMA 20, 50, 200), Supertrend, MACD.
 - **Momentum/Oscillators:** RSI, Bollinger Bands, Relative Strength (RS) against CNXPHARMA.
 - **Volume:** Volume bars, Moving Averages, Distribution/Accumulation signals.
 - **Fundamentals:** Revenue, Net Income, EPS growth, Analyst ratings.
- **Data Missing:**
 - Specific Institutional holding changes (FII/DII data) over the last quarter are not explicitly detailed in the text, though volume analysis gives clues.
- **Confidence Level: High.** The report provides a full technical suite (Trend, Momentum, Volatility, and Volume) alongside fundamental context.
 - *Note:* The report dates reference **early 2026**. I will analyze this as a simulation or forward-projection based on the data provided in the charts, treating "Current" as Feb 7, 2026.

Step 2: Analyze the Setup

Price Structure & Trend:

- **Consolidation:** The stock has been in a corrective phase since late 2024, correcting from ~1900 to ~1550. It is currently in a **consolidation/basing pattern** around the 1700 level.
- **EMA Convergence (High Importance):** A critical technical development is visible on Page 6 and 7. The EMA 20 (1665), EMA 50 (1688), and EMA 200 (1685) are tightly clustered. The price (1695) is currently sitting *just above* this cluster. This "knot" of moving averages indicates volatility contraction and often precedes a significant expansion (breakout).
- **Supertrend Hurdle:** Despite being above the EMAs, the stock is still below the Daily Supertrend resistance at **1704.88** (Page 10).

Momentum:

- **MACD: Bullish.** The MACD line has crossed above the Signal line (Page 12), and the histogram is expanding positively, suggesting momentum is shifting to the upside.
- **RSI:** Neutral at 54.72, but rising from oversold levels, leaving ample room for upside before becoming overbought.

Relative Strength:

- While the 1-Year RS is neutral/lagging, the short-term RS (1M, 3M, 6M) are all effectively "Leader" status (>1.0), indicating the stock is beginning to outperform its sector peers in the immediate term.

Volume:

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

- There is evidence of "Selling Exhaustion" and "Climax Volume" (Page 18) near the recent lows, which typically marks a bottoming process.

Step 3: Formulate the Recommendation

Verdict: **NO** (Not a "Buy" at this exact second, but a high-priority "Conditional Buy").

Reasoning: While the setup is constructive due to the EMA convergence, the stock is trading essentially at resistance (Supertrend at 1704.88). A rejection here could lead to further chopping. As a risk-averse positional trader, we need price confirmation that the buyers have absorbed the supply at 1700-1705 before committing capital. We want to buy the *breakout* of this compression, not the middle of the noise.

Conditional Trading Plan

Condition to Buy:

- Wait for a **Daily Close above INR 1,715**.
- *Rationale:* This clears the Supertrend resistance (1704.88) and the psychological 1700 barrier, confirming that the trend has shifted from "Sell" to "Buy" and the EMA support cluster is holding.

Entry Price:

- **INR 1,715 - INR 1,725** (Enter on the confirmed breakout).

Stop Loss:

- **INR 1,635** (Closing Basis).
- *Rationale:* This places the stop below the tight cluster of EMAs (20, 50, 200) and the recent consolidation lows. If price closes back below 1640, the breakout has failed and the "knot" is acting as resistance.

Take Profit:

- **Target 1: INR 1,880** (~9.5% Upside).
 - *Rationale:* This retests the major swing highs from late 2025/early 2026.
- **Target 2: INR 1,960** (~14% Upside).
 - *Rationale:* This aligns with the "Analyst Price Target" shown in the Trendlyne snapshot (Page 24).

Risk/Reward Analysis: * Risk: ~4.5% * Reward: ~9.5% to 14% * Ratio: ~1:2 to 1:3 (Favorable)

Candlestick Classification Analysis

Based on the **Candlestick Classification Report (Page 20)** and the **Chart Visuals (Page 21)**, here is my analysis as a Price Action Trader.

Executive Summary: The "Wait-and-See" Equilibrium

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

- **Current Classification: No Control (0)**
- **10-Day Trend Score: 0.00 (Neutral)**
- **Immediate Bias: Neutral to Bearish** (Pause within a downtrend)

The market has entered a state of complete indecision. The "No Control" status combined with a flat 10-day average score of 0.00 indicates that the fierce battle between buyers and sellers has resulted in a stalemate around the INR 1695 level.

Detailed Price Action Breakdown

1. The Current Candle: "No Control" (Grey)

Looking at the far right of the chart on Page 21, the latest candle is colored **Grey**.* **Anatomy**: It appears to be a small-bodied candle (likely a Doji or Spinning Top) with wicks on both sides.* **Logic (Algorithm Step 3 & 1)**: The "No Control" classification tells us the body size was likely $<0.5 \text{ ATR}$ (weak conviction), or the wicks were long enough to neutralize the body direction.* **Interpretation**: Neither the bulls nor the bears were willing to hold positions overnight. The price discovery mechanism is currently broken at this level.

2. The Context: A Failed Recovery?

To understand where the price is going, we must look at where it came from:* **The Drop**: Prior to this consolidation, there was a sharp decline from the ~1750-1800 levels down to ~1580.* **The Bounce**: We saw a few **Light Green (Buyer Control)** candles pushing price back up to current levels.* **The Stall**: The recovery has lost momentum. We are seeing **Light Red (Seller Control)** candles mixing with **Grey (No Control)** candles. This suggests the "Buy the Dip" crowd is running out of steam, and sellers are stepping back in to defend lower highs.

3. Volume Validation (The Critical Multiplier)

- **Observation**: On the bottom pane of Page 21, looking at the recent "Sell" moves (Red bars), the volume spikes were significantly higher (some reaching Seller Strong Control intensity).
- **Current Volume**: The volume during this current "No Control" phase and the recent bounce appears average to low.
- **Trader's Axiom**: "Price requires volume to rise, but can fall under its own weight." The lack of "High Volume" (Algorithm Step 4) on the green candles suggests this is a **weak retracement**, not a trend reversal.

Prediction: Which side will the price move?

My analysis predicts a **continuation to the DOWNSIDE**, testing the recent lows (INR 1580-INR 1600).

Why?1. **Bearish Consolidation**: In a short-term downtrend, a period of "No Control" (0.00 score) usually acts as a "**Bearish Flag**" or a pause before the next leg down.2. **Lack of Conviction**: There are almost no **Buyer Strong Control (+2)** candles in the recent cluster. Without a "Body $> 1.5 \text{ ATR}$ + High Volume" candle to break the INR 1720 resistance, bulls have no fortress.3. **Wick Rejection**: The presence of upper wicks on

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

recent candles (downgrading them to "No Control" or "Seller Control") shows that every time price tries to push higher, it gets sold into.

Trading Plan (The Setup)

- **The Trap (Don't Buy Yet):** Do not be fooled by the stability. A "No Control" candle is often the calm before volatility expands.
- **The Short Trigger:** If we see a **Seller Control (-1)** candle that closes below **INR 1680**, it confirms the pause is over and the downtrend is resuming.
- **The Bullish Invalidation:** I would only change my bias to **Bullish** if I see a **Buyer Strong Control (+2)** candle (Large Green Body + High Volume) closing above **INR 1735**, proving that institutions are accumulating.

Verdict: The market is resting. Expect a retest of lower support levels unless heavy volume enters immediately.

News & Analyst Targets

As a stock research analyst, I have compiled the latest news, brokerage reports, and analysis for **Sun Pharmaceutical Industries Ltd. (SUNPHARMA)** for the week ending February 7, 2026.

1) Latest News for SUNPHARMA This Week

- **Strong Q3 FY26 Earnings:** On January 31, 2026, Sun Pharma reported a robust set of numbers for the third quarter.
 - **Net Profit:** Jumped **16% YoY** to **INR 3,369 crore**, beating street estimates.
 - **Revenue:** Grew **13.5% YoY** to **INR 15,520 crore**, driven by strong performance in India, Emerging Markets, and its Global Specialty portfolio.
 - **EBITDA:** Surged **23.4% YoY** with margins expanding to **31.9%** (up from 29.3% last year), indicating improved operational efficiency.
- **Interim Dividend Declared:** The board declared an interim dividend of **INR 11 per share** for FY26. The record date was set for February 5, 2026.
- **New Investment in Assam:** The company announced a plan to invest **INR 500 crore** to set up a new manufacturing facility in Assam, which is expected to generate employment for over 500 people.
- **Legal Battle on Semaglutide:** There is an ongoing legal tussle with Novo Nordisk regarding the "weight-loss drug" Semaglutide. A court order in late December permitted Sun Pharma to export the drug but barred domestic sales in India for now.

2) Upgrades or Downgrades from Brokerages

The overall sentiment remains **bullish**, but there have been some adjustments to price targets rather than outright rating downgrades.

- **Target Price Adjustments (Mixed):**
 - **Nomura** maintained its **'Buy'** rating but slightly **lowered its target price** to **INR 1,920** (from INR 1,960) on Feb 2, 2026, citing minor adjustments in estimates.
 - **MarketsMojo** downgraded the stock's technical/fundamental score from "Buy" to **"Hold"** in mid-January, citing valuation concerns after the recent rally.
- **Reiteration of 'Buy' Ratings:**

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

- Major brokerages like **Jefferies**, **Motilal Oswal**, and **JM Financial** have reiterated their '**Buy**' ratings following the Q3 results, citing confidence in the specialty portfolio and domestic growth.

3) Other News Directly or Indirectly Impacting SUNPHARMA

- US FDA Scrutiny on "Copycat" Drugs:** The US FDA Commissioner recently commented on taking swift action against unapproved "copycat" versions of weight-loss drugs (like Wegovy/Ozempic). This is relevant for Sun Pharma as it develops generic Semaglutide; strictly enforced regulations could impact the timeline or ease of entry for generics in the US market.
- Regulatory Status (Baska Facility):** In December 2025, the US FDA classified the inspection of Sun Pharma's Baska facility as "**Official Action Indicated**" (OAI). This implies that regulatory or administrative actions are recommended, which could delay approvals for products made at this specific site.
- Sector Trend:** The Nifty Pharma index has been facing some resistance, but Sun Pharma has relatively outperformed its peers due to its diversified revenue base and strong specialty drug sales (like Ilumya and Winlevi).

4) Latest Analyst Targets & Ratings (Post-Q3 FY26 Results)

Below is a summary of the latest calls from major financial institutions as of February 2026.

Brokerage Firm	Rating	Target Price (INR)	Key Rationale
JM Financial	Buy	2,392	expects continued momentum in specialty portfolio & India business.
BOB Capital Markets	Buy	2,109	Bullish on global specialty scaling and margin expansion.
Jefferies	Buy	2,100	Maintained positive outlook on specialty assets despite sector headwinds.
Emkay Global	Buy	2,000	Raised target post-results; cites strong execution in branded markets.
Motilal Oswal	Buy	1,940	Valuations reasonable; growth driven by niche launches.
Nomura	Buy	1,920	Reduced target slightly but remains positive on long-term story.
ICICI Direct	Buy	1,910	Consistent domestic growth and stable US generics business.
Prabhudas Lilladher	Buy	1,900	Steady earnings visibility and strong balance sheet.

Note: Share price targets are subject to change based on market conditions. The current market price (CMP) is hovering around the INR 1,700 level.


Stock Detailed Analysis Report

SUNPHARMA.NS

Current Price: ₹1695.10

Generated: 2026-02-07 10:30

SUNPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	12.21%	4.11%
Net Income	Yes	47.84%	5.85%
ROE	No	-32.32%	-32.32%
EPS	Yes	47.37%	16.76%

SUNPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	50.6/100
:	

== RS RATIOS ==:

1M RS:	1.008 [Leader]
3M RS:	1.026 [Leader]
6M RS:	1.048 [Leader]
1Y RS:	0.935 [Neutral]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::


✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	1Y=0.935 (≤ 1.0)
✗ Performance Improving:	Not improving

Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPHARMA
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



SUNPHARMA.NS - EMA Crossover Summary

EMA 20:	1665.23
EMA 50:	1688.86
EMA 200:	1685.14
Trend Status:	Short-term Downtrend
Golden Cross Date:	2025-11-14 00:00:00+05:30
Golden Cross Price:	1745.76


SUNPHARMA.NS EMA Crossover Analysis



SUNPHARMA.NS - Bollinger Bands Summary

Current Price:	1695.10
Upper Band:	1753.02
Middle Band (SMA 20):	1655.32
Lower Band:	1557.61
%B:	0.7036
Band Width:	0.1180
Status:	Upper Half
Signal:	None
Recent Signal 1:	Buy Signal at 2025-12-30 00:00:00+05:30
Recent Signal 2:	Buy Signal at 2026-01-20 00:00:00+05:30
Recent Signal 3:	Buy Signal at 2026-01-21 00:00:00+05:30


SUNPHARMA.NS Bollinger Bands (20, 2) Analysis



SUNPHARMA.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	1704.88
Signal Identified On:	2025-12-18

Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




SUNPHARMA.NS - MACD Summary

MACD Line:	-11.55
Signal Line:	-23.74
Histogram:	12.19
Trend:	Bullish
Momentum:	Strengthening
Signal:	None

SUNPHARMA.NS Price






SUNPHARMA.NS MACD (12, 26, 9)



SUNPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.1180
ATR:	43.7936
Total Signals:	9
Signal 1:	BB Squeeze at 2025-12-15 00:00:00+05:30 (Price: 1785.50)
Signal 2:	BB Squeeze at 2025-12-16 00:00:00+05:30 (Price: 1769.80)
Signal 3:	BB Squeeze at 2025-12-17 00:00:00+05:30 (Price: 1781.33)
Signal 4:	ATR Contraction at 2026-01-02 00:00:00+05:30 (Price: 1716.85)
Signal 5:	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 1717.74)


SUNPHARMA.NS - Volatility Squeeze Analysis



SUNPHARMA.NS - RSI-Volume Summary

Current RSI:	54.72
Current Volume:	1277116
Volume MA 20:	3192869
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-06-04 00:00:00+05:30, Price: 1648.73
Bearish Div 1:	Date: 2024-04-01 00:00:00+05:30, Price: 1598.69
Bearish Div 2:	Date: 2025-07-30 00:00:00+05:30, Price: 1722.61

SUNPHARMA.NS RSI-Volume Divergence Analysis



SUNPHARMA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:

38 Signals Detected

:

2025-12-29 [+]:

Selling Exhaustion (Bullish Div)

2026-01-08 [-]:

Distribution Day

2026-01-21 [-]:

Distribution Day



2026-01-29 [-]:

Distribution Day

2026-02-03 [-]:

Climax Volume (Churning)

SUNPHARMA.NS - Volume Analysis



SUNPHARMA.NS - Candlestick Classification Summary

== CANDLESTICK CLASSIFICATION ==:

Latest Classification: **No Control**

Recent Trend Score (10-day avg): 0.00

:

Distribution:

No Control: 118

Buyer Control: 58

Seller Control: 49

Seller Strong Control: 3

SUNPHARMA.NS - Candlestick Classification




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	1761.01	1695.1	2026-01-12
1 Day	DOWNTREND (Sell)	1715.95	1695.1	2025-12-18
15 Min	DOWNTREND (Sell)	1703.51	1696.0	2026-02-06

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	No Signal
1 Day	Bullish	Strengthening	No Signal
15 Min	Bullish	Strengthening	No Signal

SUNPHARMA.NS - 1 Week (Candlestick + EMAs)




SUNPHARMA.NS - 1 Day (Candlestick + EMAs)



SUNPHARMA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - SUNPHARMA_main



Trendlyne Snapshot - SUNPHARMA_forecaster

Markets

STARFOLIO

Alerts

F&O

MF

Reports

Screeners

Subscribe

Superstars

Portfolio

Watchlist

Insider Trades

Results

Data Downloader

More

Search Stock, IPO, MF

India

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [SUN PHARMACEUTICAL INDUSTRIES LTD.](#)

Sun Pharmaceutical Industries Ltd. ⓘ

NSE: SUNPHARMA | BSE: 524715

Mid-range Performer ⓘ

In 6 Starfolio Baskets

1695.10 -7.50 (-0.44%)

1.3M NSE+BSE Volume

NSE 06 Feb, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

Sun Pharmaceutical - SUNPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 38 analysts

Sun Pharmaceutical has a share price target of Rs 1963, revenue growth forecast of 10.5%, and profit growth estimate of 5.8% for FY26, based on top 38 analyst calls.

Sun Pharmaceutical FORECASTER - Analyst Estimates ⓘ

[FORECASTER DASHBOARD →](#)

SHARE PRICE TARGET FORECAST

12 MONTH ESTIMATE

LOW ESTIMATE 1550 HIGH ESTIMATE 2450

● CURRENT PRICE ● AVG. ESTIMATE

HIT Sun Pharmaceutical's share price target is above the current price, with an upside of 15.8%

EPS FORECAST

QUARTER ANNUAL

● ACTUAL EPS ● AVG. ESTIMATE

MISS Sun Pharmaceutical's EPS was lower than average estimate 2 times in past 3 years

CONSENSUS RECOMMENDATION

38 ANALYST Recommendations

BUY

22	9	3	2	2	Sep '25
22	9	3	2	2	Oct '25
22	11	1	2	2	Nov '25
22	11	1	2	2	Dec '25
22	11	1	2	2	Jan '26
24	10	2	2		Feb '26

● STRONG BUY ● BUY ● HOLD ● SELL ● STRONG SELL

The consensus recommendation from 38 analysts for Sun Pharmaceutical is BUY